Advy Japan CO Limited Pharmaceutical Import Profile — Japan (DGFT 2022–2026)

Name: Advy Japan CO Limited Pharmaceutical Import Records from India — 2 Products, $711.4K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Advy Japan CO Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $711.4K Trade | TransData Nexus

Advy Japan CO Limited

Pharmaceutical Importer · Japan · Medical Devices & Diagnostics Focus · $711.4K Total Trade · DGFT Verified

Advy Japan CO Limited is a pharmaceutical importer based in Japan with a total trade value of $711.4K across 2 products in 1 therapeutic categories. Based on 194 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Advy Japan CO Limited sources from 1 verified Indian supplier, with Advy Chemical Private Limited accounting for 100.0% of imports.

Advy Japan CO Limited — Import Portfolio & Supplier Network

Advy Japan CO Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Advy Japan CO Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Advy Chemical Private Limited	$180.5K	64	100.0%

Advy Japan CO Limited sources from 1 verified Indian supplier across 22 distinct formulations. The sourcing is highly concentrated — Advy Chemical Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Advy Japan CO Limited Import?

Formulation	Value	Ships
Diagnostic reagents goat anti- human	$59.2K	3
Diagnostic reagents goat anti- human albumin whole	$46.9K	2
Diagnostic reagents goat anti- human albumin whole	$24.1K	2
Diagnostic reagents goat anti- human iga fractionated item code -	$16.8K	1
Goat anti- human albumin whole	$12.6K	1
Diagnostic reagents goat anti- human	$7.4K	3
Diagnostic reagents goat anti- human	$5.1K	2
Diagnostic reagents goat anti- human igg fc	$4.0K	1
Diagnostic reagents goat anti- human	$2.0K	1
Diagnostic reagents goat anti- human iga fractionated item code -	$488	1
Diagnostic reagents anti-crp serum	$420	35
Diagnostic reagents goat anti - humanigm -	$308	2
Diagnostic reagents immuglo 100 ML	$262	1
Diagnostic reagents goat anti- human crp whole serum item code	$238	1
Diagnostic reagents goat anti- human crp whole serum item code	$238	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Diagnostic	Medical Devices & Diagnostics	$355.7K	97	1.0%	12
2	Reagent	Medical Devices & Diagnostics	$355.7K	97	1.4%	10

Advy Japan CO Limited imports 2 pharmaceutical products across 1 categories into Japan totaling $711.4K.

Advy Japan CO Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Advy Japan Co., Ltd., established on April 1, 2008, is a pharmaceutical importer and buyer headquartered in Tokyo, Japan. The company operates as an affiliate of Bharat Serums and Vaccines Limited (BSVL), a prominent Indian pharmaceutical firm specializing in biological and biotechnological products. Advy Japan's primary focus is on the importation and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, sourced from India. This strategic partnership enables Advy Japan to leverage BSVL's extensive product portfolio and global network, facilitating the introduction of high-quality pharmaceutical products into the Japanese market. (advy-japan.jp)

The company's product offerings encompass a range of diagnostic reagents, pharmaceutical preparations, and active pharmaceutical ingredients (APIs). Advy Japan is dedicated to forming successful and transparent business relationships with its customers in Japan by supplying globally recognized high-end products coupled with local support and direct service. Additionally, Advy Japan serves as a strategic gateway to introduce its customers' novel products and technical-oriented services to the world market from Japan. (advy-japan.jp)

2Distribution Network

Advy Japan Co., Ltd. operates from its headquarters located at Kanda No.4 Park Bldg., 2nd Floor, 1-4-4, Iwamotocho, Chiyoda-ku, Tokyo 101-0032, Japan. While specific details regarding warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Tokyo suggests access to a robust distribution network. This central location facilitates efficient importation and distribution of pharmaceutical products throughout Japan. Advy Japan's affiliation with BSVL and its global network likely provides additional logistical support, enhancing its ability to source and distribute products internationally. (advy-japan.jp)

3Industry Role

Advy Japan Co., Ltd. functions as a pharmaceutical importer and distributor within Japan's pharmaceutical supply chain. By sourcing finished pharmaceutical formulations from India, the company plays a crucial role in introducing and supplying these products to the Japanese market. This position enables Advy Japan to bridge the gap between Indian pharmaceutical manufacturers and Japanese healthcare providers, ensuring the availability of a diverse range of pharmaceutical products to meet local demand. (advy-japan.jp)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Advy Japan CO Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Advy Japan Co., Ltd. demonstrates a high degree of sourcing concentration, importing finished pharmaceutical formulations exclusively from a single supplier, Advy Chemical Private Limited (ACPL), which accounts for 100% of its imports. This singular sourcing strategy indicates a deep, strategic partnership between Advy Japan and ACPL, facilitating streamlined procurement processes and potentially favorable terms. However, this dependency also introduces risks associated with supply chain disruptions, such as production delays or quality control issues at the supplier's end. The stability of this relationship is evidenced by the consistent volume of shipments—64 shipments totaling $181K USD—suggesting a reliable and ongoing collaboration. (advy-japan.jp)

2Supply Chain Resilience

The resilience of Advy Japan Co., Ltd.'s supply chain is closely tied to its exclusive reliance on Advy Chemical Private Limited (ACPL) for sourcing finished pharmaceutical formulations. While this focused sourcing strategy may offer operational efficiencies, it also exposes Advy Japan to potential risks associated with supply chain disruptions, such as production delays or quality control issues at the supplier's end. The stability of this relationship is evidenced by the consistent volume of shipments—64 shipments totaling $181K USD—suggesting a reliable and ongoing collaboration. However, the lack of publicly available information regarding backup suppliers or alternative sourcing strategies indicates a potential vulnerability in the supply chain. To enhance resilience, Advy Japan may consider diversifying its supplier base and establishing contingency plans to mitigate potential disruptions.

Importing Pharmaceuticals into Japan — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Japan

1Regulatory Authority & Framework

In Japan, the importation and distribution of pharmaceutical products are regulated by the Ministry of Health, Labour and Welfare (MHLW). The Pharmaceutical Affairs Law and the Customs Law govern these activities to ensure public safety and product efficacy. For pharmaceutical importers like Advy Japan Co., Ltd., obtaining a license from the MHLW is mandatory. This license authorizes the importation, manufacture, and sale of pharmaceutical products within Japan. The licensing process involves stringent evaluations to ensure compliance with Japan's high standards for pharmaceutical safety and quality. (mhlw.go.jp)

2Import Licensing & GMP

To import pharmaceutical products into Japan, companies must obtain a license from the Ministry of Health, Labour and Welfare (MHLW). This license is essential for the importation, manufacture, and sale of pharmaceutical products within Japan. Additionally, the MHLW requires that imported pharmaceutical products comply with Good Manufacturing Practice (GMP) standards. Recognized GMP certifications include those from the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications ensure that pharmaceutical products meet the necessary quality standards for safety and efficacy. Importers must verify that their suppliers hold valid GMP certifications to maintain compliance with Japanese regulations. (mhlw.go.jp)

Advy Japan CO Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Advy Japan Co., Ltd. focuses on importing finished pharmaceutical formulations, including diagnostic reagents, pharmaceutical preparations, and active pharmaceutical ingredients (APIs), primarily sourced from India. This strategic focus aligns with the growing demand in Japan for high-quality diagnostic and therapeutic products. The choice to import from India leverages the country's established pharmaceutical manufacturing capabilities and cost advantages. By concentrating on these specific therapeutic areas, Advy Japan aims to meet the evolving healthcare needs of the Japanese population, particularly in diagnostics and specialized treatments. (advy-japan.jp)

2Sourcing Profile

Advy Japan Co., Ltd. employs a sourcing strategy that centers on importing finished pharmaceutical formulations from a single supplier, Advy Chemical Private Limited (ACPL). This approach allows for streamlined procurement processes and potentially favorable terms due to the deep, strategic partnership between the two companies. The focus on finished formulations, rather than raw active pharmaceutical ingredients (APIs), indicates a preference for ready-to-market products that can be directly distributed within Japan. This strategy aligns with Advy Japan's objective to provide high-quality pharmaceutical products to the Japanese market efficiently. (advy-japan.jp)

Market Positioning

Frequently Asked Questions — Advy Japan CO Limited

What products does Advy Japan CO Limited import from India?

Advy Japan CO Limited imports 2 pharmaceutical products across 1 categories. Top imports: Diagnostic ($355.7K), Reagent ($355.7K).

Who supplies pharmaceuticals to Advy Japan CO Limited from India?

Advy Japan CO Limited sources from 1 verified Indian suppliers. The primary supplier is Advy Chemical Private Limited (100.0% of imports, $180.5K).

What is Advy Japan CO Limited's total pharmaceutical import value?

Advy Japan CO Limited's total pharmaceutical import value from India is $711.4K, based on 194 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Advy Japan CO Limited focus on?

Advy Japan CO Limited imports across 1 categories. The largest: Medical Devices & Diagnostics (100.0%).

Get Full Advy Japan CO Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.